Executive Summary
DOE awarded a $1.96B cost-plus award fee contract to nonprofit FERMI FORWARD DISCOVERY GROUP, LLC for Fermi National Accelerator Laboratory (FNAL) management through 2029-12-31, with $595M outlayed to date, signaling stable multi-year R&D funding in physical sciences. This full-and-open competition award to a Chicago-based entity underscores DOE commitment to GOCO operations amid neutral market signals.
Investors face execution risks from performance fees and budget exposure, but $7.4M options upside and extension potential offer long-term upside.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Investment Signals (1)
- $1.96B FNAL operations contract awarded (HIGH)▲
Provides predictable multi-year revenue through 2029 for high-energy physics R&D under NAICS 541715.
Risk Flags (2)
- Execution [MEDIUM RISK]▼
Award fees contingent on GOCO management performance at FNAL.
- Market [HIGH RISK]▼
5-year term vulnerable to DOE budget cuts or congressional delays.
Opportunities (1)
- ◆
$7.4M embedded in base + options ($1.97B total); follow-on contracts post-2029 likely.
Sector Themes (1)
- ◆
Massive $1.96B nonprofit award for FNAL highlights DOE priority on accelerator science infrastructure.
Watch List (2)
- 👁
{"entity"=>"FERMI FORWARD DISCOVERY GROUP, LLC", "reason"=>"$1.96B revenue anchor with $595M outlayed; sole focus of period's contract activity.", "trigger"=>"Options exercise notices or performance shortfalls"}
- 👁
{"entity"=>"DOE Energy Sciences Budget", "reason"=>"Drives FNAL contract viability over 5-year horizon.", "trigger"=>"<5% YoY funding growth or rescissions"}
Get daily alerts with 1 investment signals, 2 risk alerts, 1 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 26, 2026
US Pre-Market SEC Filings Roundup — May 26, 2026
US Pre-Market SEC Filings Roundup
May 26, 2026
Biotech Small-Cap Approvals — May 26, 2026
Biotech Small-Cap Approvals
May 26, 2026
Big Pharma Approvals — May 26, 2026
Big Pharma Approvals